
- Vol 39, Issue 12
Use of Antipsychotics: Risks of Tardive Dyskinesia
"This study served as a sobering reminder of the significant frequency of this disfiguring and sometimes disabling adverse effect, which can be irreversible."
A recent study found a 5.1% prevalence rate of
The study results were consistent with previously identified TD rates from second-generation antipsychotics (SGAs) found in meta-analyses—for example, a study by Carbon and colleagues2 that found an annualized rate of 2.6% per year. Risk factors that increase the rate include use in mood disorders, older individuals, women, those with alcohol use disorder, those with diabetes and cigarette dependence, and those who use anticholinergic drugs.
Additionally, a second meta-analyses by Carbon et al found a significantly greater risk of TD in participants who were actively taking a first-generation antipsychotic (FGA) compared with an SGA.3 The investigators analyzed 41 studies, which included 11,493 participants on antipsychotic medications and demonstrated an overall prevalence of TD in 25.3% of participants. Participants taking FGAs had a 30.0% prevalence of TD, while participants taking SGAs had a 20.7% prevalence of TD. The rate was 7.2% in the small number of studies (N = 4) involving patients who had only been on SGAs.
There are now 10 SGAs that are US Food and Drug Administration (FDA)–approved for acute mania, bipolar depression, and/or maintenance treatment in bipolar disorder, and their use has increased 4-fold in recent years.4 Notably, it still seems common for haloperidol to be used in managing severe mania; this puts those patients at greater risk for later TD even if they are switched to and maintained on SGAs.
The patients in the new study were on antipsychotics for a mean of 18 years, and the mean dose was equivalent to about 6 mg of haloperidol;
78% of their trials were with SGAs. Bipolar I disorder was associated with greater risk, probably because individuals with bipolar I disorder were more likely to receive antipsychotics.1
The widely accepted Schooler and Kane criteria for diagnosing TD require ruling out other potential causes of the movements, some of which are poorly fitting dentures or other dental problems, parkinsonian symptoms, restless leg syndrome, and Huntington and Wilson diseases.5 Then, using the Abnormal Involuntary Movement Scale, there should be 1 body area with a score of at least 3 (moderate severity) or 2 areas with mild movements (score of 2). The patient should have been taking an antipsychotic for at least 3 months.
There are alternative FDA-approved treatments for long-term maintenance of patients with bipolar disorder that would involve minimal risk of this adverse effect, including lithium and lamotrigine. (Reminder: Valproate and carbamazepine have not been approved for maintenance treatment.) Informed consent discussions of treatment options should certainly include the potential risk of TD with antipsychotics, but it seems (from consulting on many bipolar cases) that this often does not occur. There are other significant adverse effects from SGAs including drug-induced parkinsonism, akathisia, dystonias, significant weight gain, prolactin elevation,6 hyperlipidemia, hyperglycemia, onset of type 2 diabetes, and more.
Regarding treatment of TD, we now have 2 FDA-approved options: deutetrabenazine and valbenazine. They are expensive, and in some settings—including certain VA hospitals—they still require off-formulary approval. According to 1 meta-analysis of efficacy, valbenazine seemed to have somewhat more efficacy with a number needed to treat (NNT) of 4 versus a NNT of 7 for deutetrabenazine,7 but the other analysis concluded that both had NNTs of 5.8,9 There have been no head-to-head comparisons. Deutetrabenazine has a short half-life and requires twice-daily dosing. Adverse effects of the 2 agents in studies of patients with TD seem comparable.
Dr Osser is associate professor of psychiatry at Harvard Medical School and codirector, US Department of Veterans Affairs, National Bipolar Disorder Telehealth Program, in Brockton, Massachusetts. The author reports no conflicts of interest concerning the subject matter of this article.
References
1. Gardea-Resendez M, Taylor-Desir MJ, Romo-Nava F, et al.
2. Carbon M, Kane JM, Leucht S, Correll CU.
3. Carbon M, Hsieh CH, Kane JM, Correll CU.
4. Rhee TG, Olfson M, Nierenberg AA, Wilkinson ST.
5. Schooler NR, Kane JM.
6. Osser DN.
7. Solmi M, Pigato G, Kane JM, Correll CU.
8. Citrome L.
9. Citrome L.
Articles in this issue
almost 3 years ago
Current Treatments for Cannabis Use Disorderalmost 3 years ago
The Importance of Cherishing the Older Adults in Your Lifealmost 3 years ago
Dementia in the Newsalmost 3 years ago
Beyond Counting Sheep: Helping Patients With Insomniaalmost 3 years ago
Eight Best Practices for Medical Malpractice Defensealmost 3 years ago
Psychopharmacology Conference Offers New Research, Prescribing Tipsalmost 3 years ago
On Transiencealmost 3 years ago
Beyond “Bad Behavior”: ADHD in Clinical PracticeNewsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.